Unlike AML cell lines with low PIK3R5 and PIK3CG, cells highly expressing PIK3R5 or PIK3CG are more sensitive to their loss and treatment with the PI3Kγ inhibitor eganelisib. The gene discussed is PIK3R5; the disease is acute myeloid leukemia.